This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
This is not CLL/SLL specific. But wouldn’t any immunocompromised (IC) patient feel safer if they knew there was a five-day course of an oral anti-viral medication PAXLOVID™ (PF-07321332; ritonavir), that when taken early after contracting COVID-19 gave a nine out of ten chance of preventing hospitalization and death?
That dream moved closer to a reality today with the Emergency Use Authorization (EUA) submission by Pfizer for PAXLOVID™ (PF-07321332; ritonavir).
With promising antibodies active for pre-exposure prophylaxis (PreP) and potent therapeutics close to becoming accessible, the world may soon feel a bit safer for those with chronic lymphocytic leukemia/small lymphocytic lymphoma, as well as others who are immunocompromised.
Here is Pfizer’s press release.
Stay strong. We are all in this together.
Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP, and Chief Medical Officer
CLL Society, Inc.